An increased understanding of the predisposing genetics and complex pathogenic mechanisms of Alzheimer's disease have facilitated delineation of the long pre-clinical course and re-invigorated the search for disease-modifying treatments. Establishment of accurate blood-based biomarkers has enabled pre-clinical identification of early disease and permits trials of preventative treatment and quantitative monitoring of therapeutic effects. The broad range of therapeutic possibilities encompasses gene editing, enzyme activators and inhibitors, antisense oligonucleotides, and antagonists of receptors for inflammatory mediators.
Elsevier, The American Journal of Medicine, Available online 27 August 2024